HSPA5 and prostate carcinoma: Genes associated with ETV4-fusion-positive prostate cancers were used as the input, and four therapeutic candidate targets, PARP1, NQO1, HSPA5, and TOP1, and the respective selective drugs, olaparib, amrubicin, fluorouracil, and irinotecan, were identified.